Prostatype Genomics AB
PGO0
Company Profile
Business description
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
Contact
Augustendalsvagen 20
Nacka Strand131 52
SWET: +46 8208700
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
6
Stocks News & Analysis
stocks
Progress in UK expansion for undervalued ASX share
Guidance reaffirmed and UK implementation on track.
stocks
The sectors set to soar on government spending
Governments worldwide love to spend more money, and there are no signs that it will change any time soon.
stocks
Chart of the Week: How private companies are reshaping public markets
Our latest take from the US Manager Research team.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,098.60 | 9.70 | -0.11% |
| CAC 40 | 7,964.77 | 109.46 | -1.36% |
| DAX 40 | 23,734.02 | 315.72 | -1.31% |
| Dow JONES (US) | 47,038.96 | 272.04 | -0.58% |
| FTSE 100 | 9,735.78 | 41.30 | -0.42% |
| HKSE | 26,485.90 | 550.49 | 2.12% |
| NASDAQ | 23,199.39 | 300.40 | -1.28% |
| Nikkei 225 | 50,883.68 | 671.41 | 1.34% |
| NZX 50 Index | 13,576.81 | 44.17 | -0.32% |
| S&P 500 | 6,749.24 | 47.05 | -0.69% |
| S&P/ASX 200 | 8,828.30 | 8.50 | -0.10% |
| SSE Composite Index | 4,007.76 | 38.51 | 0.97% |